Evidence map›Paper›PMID 41601680›Full record

ArticleFrontiers in immunology2025

SARS-CoV-2 evolution enhances endocytic uptake while preserving TMPRSS2-dependent fusion.

Clara L Magnus, Zeliha Hamed Jaber, Andreas Hiergeist, Lisa Arnold, Harriet Marchel, Antonia Lamprecht, Frank Hanses, Thomas Dienemann, Roland Schneckenpointner, Matthias Lubnow and 11 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Clara L MagnusInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Zeliha Hamed JaberInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Andreas HiergeistInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Lisa ArnoldInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Harriet MarchelInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Antonia LamprechtInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Frank HansesEmergency Department, University Hospital Regensburg, Regensburg, Germany.
Thomas DienemannDepartment of Surgery, University Hospital Regensburg, Regensburg, Germany.
Roland SchneckenpointnerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Matthias LubnowDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Thomas MüllerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Dirk LunzDepartment of Anesthesiology, University Hospital Regensburg, Regensburg, Germany.
Florian HitzenbichlerDepartment of Infection Prevention and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany.
Stephan SchmidDepartment of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany.
Martina MüllerDepartment of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany.
Hendrik PoeckDepartment of Department of Internal Medicine 3, University Medical Center, Regensburg, Germany.
Bernhard GrafDepartment of Anesthesiology, University Hospital Regensburg, Regensburg, Germany.
Bernd SalzbergerDepartment of Infection Prevention and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany.
André GessnerInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Barbara SchmidtInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Philipp SchusterInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Of the five SARS-CoV-2 variants-of-concern (VOC), Omicron shows increased transmissibility and infectivity, but lower pathogenicity. This drop in virulence was associated with an altered entry of VOC Omicron into airway epithelia by endocytosis instead of direct fusion, increasing virus replication in the upper airways and decreasing spread to the lower respiratory tract. Methods: We aimed to assess the extent of direct fusion and endocytosis in nine clinical SARS-CoV-2 isolates collected during the SARS-CoV-2 pandemic, comprising wild-type (n=1), Alpha (n=2), Delta (n=1), and Omicron (n=5) strains. Viral entry was investigated in four different human cell lines in the presence of camostat, an inhibitor of TMPRSS2-mediated fusion, and aloxistatin, a cathepsin protease inhibitor blocking viral endocytic entry (0.024-100 µM). Full-length viral genomes were obtained using next generation sequencing. Results: Alpha and Delta variants predominantly entered Calu-3 and Caco-2 cells through TMPRSS2-dependent membrane fusion, whereas Omicron variants - particularly BE.1.1 and BA.5 - showed a pronounced shift toward endocytosis in A549 Conclusions: All Omicron variants retained TMPRSS2-dependent fusion activity, indicating that VOC Omicron broadened rather than shifted its cell tropism. While replication in the upper airways and transmissibility are enhanced, the capacity to infect the lower respiratory tract is preserved, which may pose a risk for immunocompromised individuals. The combination of Δ69/Δ70, L452R, and mutations at position 486 may confer a selective advantage, as this constellation is now prevalent in nearly all circulating SARS-CoV-2 lineages.

Indexed as

COVID-19EndocytosisSARS-CoV-2Serine EndopeptidasesVirus InternalizationCaco-2 CellsCell LineEstersGuanidinesHumansVirus ReplicationcamostatEstersGuanidinesSerine EndopeptidasesTMPRSS2 protein, humancoronavirusendocytosisevolutionfusionSARS-CoV-2tropismvariants-of-concernviral entry

Identifiers

PMID41601680
PMCPMC12832645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.